Overall, our study provides novel findings in which a DNA vaccine targeting TAAs frequently expressed in HNSCC is able to enhance the efficacy of anti-PD-1 therapy in preclinical settings. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.